London-based Bryan, Garnier & Co, an independent investment bank catering to European healthcare and technology-related companies, has appointed Alex Cogut as head of healthcare equity research to lead the bank’s team of seven healthcare analysts based across mainland Europe and the UK.

In addition to traditional equity research, the team’s focus will be on developing differentiated thought leadership that identifies long-term trends shaping the future of the healthcare sector.

Alex was previously co-head of life sciences research at Kempen & Co and has extensive experience in European biotech and medtech. At Kempen & Co he was also a board member of the life sciences franchise responsible for overall strategy and execution. He is based in Amsterdam and will divide his time between London, Paris and Amsterdam.

Olivier Garnier, founder and managing partner of Bryan Garnier said: “Alex is a prime example of the talent we have at Bryan Garnier. His appointment comes at an exciting time for the firm as we expand and revolutionise our research offering to ensure that clients continue to benefit from differentiated insights that leverage our analysts’ unique sector expertise and focus on the public and private markets.”

John Klein, head of equity research at Bryan Garnier commented: “[Alex’s] experience and deep healthcare and biotech knowledge, coupled with his strong investor relationships from financial sponsors through to institutional investors, make him a strong addition to Bryan Garnier and the ideal candidate to lead the team.”

Cogut added: “I am thrilled to be joining Bryan Garnier to lead a team of experienced analysts with strong sector knowledge. Moreover, I look forward in leveraging Bryan Garnier’s unique positioning as the go-to investment bank for European growth companies to bring valuable and comprehensive insights to investors and corporate clients across the European healthcare public and private markets.”